Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma.

Colosia A, Khan S, Hackshaw MD, Oglesby A, Kaye JA, Skolnik JM.

Sarcoma. 2016;2016:3597609. doi: 10.1155/2016/3597609. Epub 2016 Jul 19. Review.

2.

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Flinn IW, Bartlett NL, Blum KA, Ardeshna KM, LaCasce AS, Flowers CR, Shustov AR, Thress KS, Mitchell P, Zheng F, Skolnik JM, Friedberg JW.

Eur J Cancer. 2016 Feb;54:11-17. doi: 10.1016/j.ejca.2015.10.005. Epub 2015 Dec 18.

PMID:
26707592
3.

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D, Garrett CR, Skolnik JM, Rubin EH, Smith PD, Huang P, Learoyd M, Shannon KA, Morosky A, Tetteh E, Jou YM, Papadopoulos KP, Moreno V, Kaiser B, Yap TA, Yan L, de Bono JS.

Clin Cancer Res. 2015 Feb 15;21(4):739-48. doi: 10.1158/1078-0432.CCR-14-1901. Epub 2014 Dec 16.

4.

Risk assessment of drug interaction potential and concomitant dosing pattern on targeted toxicities in pediatric cancer patients.

Barrett JS, Patel D, Dombrowsky E, Bajaj G, Skolnik JM.

AAPS J. 2013 Jul;15(3):775-86. doi: 10.1208/s12248-013-9489-z. Epub 2013 Apr 18.

5.

Modeling and simulation approaches to evaluate pharmacokinetic sampling contamination from central venous catheters in pediatric pharmacokinetic studies of actinomycin-D: a report from the children's oncology group.

Edwards AY, Skolnik JM, Dombrowsky E, Patel D, Barrett JS.

Cancer Chemother Pharmacol. 2012 Jul;70(1):83-94. doi: 10.1007/s00280-012-1878-y. Epub 2012 May 24.

6.

A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies.

Gerecitano JF, Stephenson JJ, Lewis NL, Osmukhina A, Li J, Wu K, You Z, Huszar D, Skolnik JM, Schwartz GK.

Invest New Drugs. 2013 Apr;31(2):355-62. doi: 10.1007/s10637-012-9821-y. Epub 2012 May 22.

PMID:
22615058
7.

A reliable and safe method of collecting blood samples from implantable central venous catheters for determination of plasma gentamicin concentrations.

Chen J, Boodhan S, Nanji M, Chang A, Sekharan S, Lavoratore S, Brandão LR, Skolnik JM, Dupuis LL.

Pharmacotherapy. 2011 Aug;31(8):776-84. doi: 10.1592/phco.31.8.776.

PMID:
21923604
8.

Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group.

Langholz B, Skolnik JM, Barrett JS, Renbarger J, Seibel NL, Zajicek A, Arndt CA.

Pediatr Blood Cancer. 2011 Aug;57(2):252-7. doi: 10.1002/pbc.22882. Epub 2010 Dec 1.

9.

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors.

Infante JR, Kurzrock R, Spratlin J, Burris HA, Eckhardt SG, Li J, Wu K, Skolnik JM, Hylander-Gans L, Osmukhina A, Huszar D, Herbst RS.

Cancer Chemother Pharmacol. 2012 Jan;69(1):165-72. doi: 10.1007/s00280-011-1667-z. Epub 2011 Jun 3.

PMID:
21638123
10.

Approaches to clear residual chemotherapeutics from indwelling catheters in children with cancer.

Skolnik JM, Zhang AY, Barrett JS, Adamson PC.

Ther Drug Monit. 2010 Dec;32(6):741-8. doi: 10.1097/FTD.0b013e3181fa3c68.

11.

Discrete event simulation applied to pediatric phase I oncology designs.

Barrett J, Skolnik J, Jayaraman B, Patel D, Adamson P.

Clin Pharmacol Ther. 2008 Dec;84(6):729-33. doi: 10.1038/clpt.2008.193. Epub 2008 Oct 15. Review. No abstract available.

PMID:
18923388
12.

A SAS-based solution to evaluate study design efficiency of phase I pediatric oncology trials via discrete event simulation.

Barrett JS, Jayaraman B, Patel D, Skolnik JM.

Comput Methods Programs Biomed. 2008 Jun;90(3):240-50. doi: 10.1016/j.cmpb.2007.12.008. Epub 2008 Feb 13.

PMID:
18276034
13.

Shortening the timeline of pediatric phase I trials: the rolling six design.

Skolnik JM, Barrett JS, Jayaraman B, Patel D, Adamson PC.

J Clin Oncol. 2008 Jan 10;26(2):190-5. doi: 10.1200/JCO.2007.12.7712.

PMID:
18182661
14.

Population pharmacokinetic investigation of actinomycin-D in children and young adults.

Mondick JT, Gibiansky L, Gastonguay MR, Skolnik JM, Cole M, Veal GJ, Boddy AV, Adamson PC, Barrett JS.

J Clin Pharmacol. 2008 Jan;48(1):35-42.

PMID:
18094218
15.

Tyrosine kinase inhibitors in pediatric malignancies.

Skolnik JM, Adamson PC.

Cancer Invest. 2007;25(7):606-12. Review.

PMID:
17952738
17.

Pediatric phase I trials in oncology: an analysis of study conduct efficiency.

Lee DP, Skolnik JM, Adamson PC.

J Clin Oncol. 2005 Nov 20;23(33):8431-41. Review.

PMID:
16293874
18.

A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer.

Skolnik JM, Barrett JS, Shi H, Adamson PC.

Cancer Chemother Pharmacol. 2006 Apr;57(4):458-64. Epub 2005 Sep 27.

PMID:
16187113

Supplemental Content

Loading ...
Support Center